HomeInsightsStock Comparison

Lyka Labs Ltd vs Zim Laboratories Ltd Stock Comparison

Lyka Labs Ltd vs Zim Laboratories Ltd Stock Comparison

Last Updated on: Jun 14, 2025

Key Highlights

  • The Latest Trading Price of Lyka Labs Ltd is ₹ 115.65 as of 13 Jun 15:30.
  • The P/E Ratio of Lyka Labs Ltd changed from 10 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Zim Laboratories Ltd changed from 27.4 on March 2020 to 32.1 on March 2025 . This represents a CAGR of 2.67% over 6 years.
  • The Market Cap of Lyka Labs Ltd changed from ₹ 36.58 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Zim Laboratories Ltd changed from ₹ 90.53 crore on March 2020 to ₹ 390.78 crore on March 2025 . This represents a CAGR of 27.60% over 6 years.
  • The revenue of Lyka Labs Ltd for the Mar '25 is ₹ 34.25 crore as compare to the Dec '24 revenue of ₹ 34.62 crore. This represent the decline of -1.07% The revenue of Zim Laboratories Ltd for the Mar '25 is ₹ 110.44 crore as compare to the Dec '24 revenue of ₹ 98.08 crore. This represent the growth of 12.6%.
  • The ebitda of Lyka Labs Ltd for the Mar '25 is ₹ 4.9 crore as compare to the Dec '24 ebitda of ₹ 6.02 crore. This represent the decline of -18.6% The ebitda of Zim Laboratories Ltd for the Mar '25 is ₹ 16.31 crore as compare to the Dec '24 ebitda of ₹ 13.32 crore. This represent the growth of 22.45%.
  • The net profit of Lyka Labs Ltd changed from ₹ -1.85 crore to ₹ 2.03 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Zim Laboratories Ltd changed from ₹ 0.23 crore to ₹ 4.88 crore over 8 quarters. This represents a CAGR of 360.62% .
  • The Dividend Payout of Lyka Labs Ltd changed from 0 % on March 2020 to 0 % on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Zim Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2025 . This represents a CAGR of 0.0% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Lyka Labs Ltd

  • Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83.
  • It also added a range of ayurvedic and animal health care products over the years.
  • In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan.
  • Lyka Exports is the subsidiary of the company.
  • The Company is engaged in the business of pharmaceutical and related activities, including research. The company offers a broad range of antibiotics used as life-savers and to treat minor infections.

About Zim Laboratories Ltd

  • Zim Laboratories Ltd was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in the State of Maharashtra.
  • The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Maharashtra, Mumbai.
  • The Company is engaged in the manufacturing of formulation on drugs and pre formulation ingredients in India and marketing and selling these within and outside India.
  • The Pharma Industry is dominated by Multinationals, Large Indian companies and in the lower end of the market large number of units mainly in the SSI sector. During the year 2019-20, ZIM Health Technologies Limited was acquired thereby resulting as a wholly owned subsidiary of the company.
  • SIA ZIM Laboratories Limited got incorporated as a wholly owned subsidiary in Latvia.

Lyka Labs Ltd News Hub

News

Lyka Labs to discuss results

Lyka Labs will hold a meeting of the Board of Directors of the Company on 26 May 2025. Pow...

Read more

15 May 2025 11:52

News

Lyka Labs EGM scheduled

Lyka Labs announced that an Extra Ordinary General Meeting (EGM) of the Company will be he...

Read more

01 Feb 2025 13:50

News

Lyka Labs announces board meeting date

Lyka Labs will hold a meeting of the Board of Directors of the Company on 4 February 2025....

Read more

03 Jan 2025 09:46

News

Lyka Labs to declare Quarterly Result

Lyka Labs will hold a meeting of the Board of Directors of the Company on 4 February 2025....

Read more

30 Dec 2024 18:47

News

Lyka Labs announces board meeting date

Lyka Labs will hold a meeting of the Board of Directors of the Company on 12 November 2024...

Read more

23 Oct 2024 10:45

News

Lyka Labs to hold board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 11 October 2024 ...

Read more

04 Oct 2024 16:39

Zim Laboratories Ltd News Hub

News

Zim Laboratories AGM scheduled

Zim Laboratories announced that the 41th Annual General Meeting(AGM) of the company will b...

Read more

04 Jun 2025 17:05

News

Zim Laboratories to announce Quarterly Result

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 20 May 20...

Read more

15 May 2025 12:30

News

Zim Laboratories partners with UAE-based Globalpharma Co.

Zim Laboratories (ZIM) has entered into a Dossier License, Product Supply, and Technology ...

Read more

09 Apr 2025 20:57

News

Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate

This authorization from INFARMED, which is the Portuguese National Authority of Medicines ...

Read more

20 Mar 2025 12:53

News

Zim Laboratories to declare Quarterly Results

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 10 Februa...

Read more

04 Feb 2025 15:18

News

ZIM Lab and Neuraxpharm announces grant of marketing authorization for Buprenorphine Sublingual Film in Europe

ZIM Laboratories and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmac...

Read more

11 Jan 2025 09:56

SWOT Analysis Of Lyka Labs Ltd

Strength

1

S

Weakness

4

W

Opportunity

1

O

Threats

1

T

SWOT Analysis Of Zim Laboratories Ltd

Strength

0

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Lyka Labs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Zim Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Lyka Labs Ltd and Zim Laboratories Ltd

Which company has a larger market capitalization, Lyka Labs Ltd or Zim Laboratories Ltd?

Market cap of Lyka Labs Ltd is 412 Cr while Market cap of Zim Laboratories Ltd is 505 Cr

What are the key factors driving the stock performance of Lyka Labs Ltd and Zim Laboratories Ltd?

The stock performance of Lyka Labs Ltd and Zim Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lyka Labs Ltd and Zim Laboratories Ltd?

As of June 14, 2025, the Lyka Labs Ltd stock price is INR ₹115.65. On the other hand, Zim Laboratories Ltd stock price is INR ₹103.82.

How do dividend payouts of Lyka Labs Ltd and Zim Laboratories Ltd compare?

To compare the dividend payouts of Lyka Labs Ltd and Zim Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions